Press Releases

Press Releases

Samsung Biologics earns ISO certifications in recognition of business excellence


• The company adds new ISO certification for compliance management and certified to updated standards for information and cloud security

• Certifications recognize Samsung Biologics’ commitment to operational excellence and demonstrates the company’s reliability and integrity as a trusted CDMO partner

 

Incheon, S. Korea, November 8, 2024 – Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO) today announced it has achieved ISO 37301:2021 certification for the first time. The company also renewed certifications for upgraded ISO 27001:2022 and ISO 27017:2015 standards. The certifications were presented by the British Standards Institution (BSI) during a ceremony held at Samsung Biologics’ headquarters.


The ISO 37301:2021, the leading standard for Compliance Management System, reflects the company’s commitment to enhance organizational governance and to comply with laws and regulations. Samsung Biologics operates a Compliance Program that promotes a culture of integrity and effectively address challenges in a rapidly evolving business environment as a reliable CDMO partner.


The company also recertified to upgraded ISO 27001:2022 (Information Security Management System) and ISO 27017:2015 (Information Security for Cloud Services), displaying continued efforts to maintain the highest standards of information and cloud security as well as data protection for clients and stakeholders. ISO 27000 family is the most recognized global set of standards for managing information security and privacy management. Samsung Biologics has been implementing best practices and principles in accordance with the international standard to enhance client satisfaction and build further trust.


“We’re pleased to obtain certification for compliance as it’s a recognition of our unwavering focus to meeting the highest standards to build deeper trust with our clients and strengthen business competitiveness,” said John Rim, CEO and President of Samsung Biologics. “Along with existing ISO certifications, we will continue to take the extra mile to strengthen ethical management while maintaining the highest security and privacy standards.”


Samsung Biologics continues to be certified across other areas, including anti-bribery management, quality management, and business continuity management.


• The company adds new ISO certification for compliance management and certified to updated standards for information and cloud security

• Certifications recognize Samsung Biologics’ commitment to operational excellence and demonstrates the company’s reliability and integrity as a trusted CDMO partner

 

Incheon, S. Korea, November 8, 2024 – Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO) today announced it has achieved ISO 37301:2021 certification for the first time. The company also renewed certifications for upgraded ISO 27001:2022 and ISO 27017:2015 standards. The certifications were presented by the British Standards Institution (BSI) during a ceremony held at Samsung Biologics’ headquarters.


The ISO 37301:2021, the leading standard for Compliance Management System, reflects the company’s commitment to enhance organizational governance and to comply with laws and regulations. Samsung Biologics operates a Compliance Program that promotes a culture of integrity and effectively address challenges in a rapidly evolving business environment as a reliable CDMO partner.


The company also recertified to upgraded ISO 27001:2022 (Information Security Management System) and ISO 27017:2015 (Information Security for Cloud Services), displaying continued efforts to maintain the highest standards of information and cloud security as well as data protection for clients and stakeholders. ISO 27000 family is the most recognized global set of standards for managing information security and privacy management. Samsung Biologics has been implementing best practices and principles in accordance with the international standard to enhance client satisfaction and build further trust.


“We’re pleased to obtain certification for compliance as it’s a recognition of our unwavering focus to meeting the highest standards to build deeper trust with our clients and strengthen business competitiveness,” said John Rim, CEO and President of Samsung Biologics. “Along with existing ISO certifications, we will continue to take the extra mile to strengthen ethical management while maintaining the highest security and privacy standards.”


Samsung Biologics continues to be certified across other areas, including anti-bribery management, quality management, and business continuity management. 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION